Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization. by Turrentine, Mark A et al.
Hindawi Publishing Corporation
Infectious Diseases in Obstetrics and Gynecology
Volume 2009, Article ID 934698, 11 pages
doi:10.1155/2009/934698
Research Article
Cost-Effectiveness of Universal Prophylaxis in Pregnancy with
Prior Group B Streptococci Colonization
Mark A. Turrentine, Mildred M. Ramirez, and Joan M. Mastrobattista
Department of Obstetrics, Gynecology and Reproductive Sciences, Kelsey Research Foundation,
University of Texas Medical School, Houston, TX 77007, USA
Correspondence should be addressed to Mark A. Turrentine, drt318@aol.com
Received 10 May 2009; Revised 7 September 2009; Accepted 8 October 2009
Recommended by Austin Ugwumadu
Objective. To estimate the costs and outcomes of rescreening for group B streptococci (GBS) compared to universal treatment of
term women with history of GBS colonization in a previous pregnancy. Study Design. A decision analysis model was used to com-
pare costs and outcomes. Total cost included the costs of screening, intrapartum antibiotic prophylaxis (IAP), treatment for mater-
nal anaphylaxis and death, evaluation of well infants whose mothers received IAP, and total costs for treatment of term neonatal
early onset GBS sepsis. Results. When compared to screening and treating, universal treatment results in more women treated per
GBS case prevented (155 versus 67) and prevents more cases of early onset GBS (1732 versus 1700) and neonatal deaths (52 versus
51) at a lower cost per case prevented ($8 805 versus $12 710). Conclusion. Universal treatment of term pregnancies with a history
of previous GBS colonization is more cost-eﬀective than the strategy of screening and treating based on positive culture results.
Copyright © 2009 Mark A. Turrentine et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Intrapartum infection with group B streptococci (GBS) may
lead to untoward neonatal sequelae such as pneumonia,
septicemia, and meningitis [1]. Several clinical trials have
demonstrated that the use of intrapartum intravenous
antibiotic prophylaxis is highly eﬀective to prevent early
onset neonatal GBS infections [1]. In August 2002, national
prevention guidelines were released from the Centers for
Disease Control and Prevention (CDC), the American
Academy of Pediatrics (AAP), and the American College of
Obstetricians and Gynecologists (ACOG) that recommend
universal antenatal culture-based screening at 35 to 37
weeks of gestation to direct treatment for the prevention
of early onset GBS disease [1, 2]. Since colonization can
be variable, the above entities recommend that practitioners
screen for GBS colonization in every pregnancy and that GBS
colonization in a previous pregnancy is not an indication for
intrapartum prophylaxis [1].
Recent longitudinal studies have demonstrated that
women colonized with GBS during pregnancy are at an
increased risk of colonization in a subsequent pregnancy
[3, 4]. Reported rates of colonization range from 38% to 53%
in subsequent pregnancies. Since many women positive for
GBS during one pregnancy remain colonized in a subsequent
pregnancy, it raises the question: Would it be cost-eﬀective
to universally administer intrapartum antibiotic prophylaxis
to all women with a history of prior GBS colonization
in a subsequent pregnancy? The aim of our study is to
estimate whether it is cost-eﬀective to base intrapartum GBS
prophylaxis on rescreening versus universal treatment of all
women with prior GBS colonization to prevent early onset
GBS disease.
2. Materials and Methods
We constructed a decision-analysis model to evaluate
the cost-eﬀectiveness of screening-directed versus universal
treatment for the prevention of early onset neonatal GBS
sepsis in women colonized with GBS in a previous pregnancy.
The pathways of events are shown in Figure 1. Since our
objective is to compare screening-directed versus direct
treatment, we limited our cost analysis to term gestations
(37 weeks and above) and excluded women with indications
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Figure 1: Decision-analysis model for evaluating the cost-eﬀectiveness of screening-directed versus universal treatment of women with
group B streptococci (GBS) colonization in a previous pregnancy on prevention of early onset neonatal GBS sepsis.
for intrapartum prophylaxis (previous neonate with invasive
GBS disease, GBS bacteriuria in the current pregnancy, and
unknown GBS status in conjunction with any of the follow-
ing amniotic membrane rupture for 18 hours or more and
intrapartum temperature 38.0◦C or more) [1]. Since current
recommendations are for culture-based screening at 35 to 37
weeks of gestation, we did not perform a subgroup analysis
for a rapid GBS test result at presentation in labor [1].
2.1. Strategies Analyzed. We compared two strategies desc-
ribed in the literature [1, 5]. With the screening strategy,
all women are cultured for GBS colonization by vaginal-
rectal swab at 35 to 37 weeks of gestation and those with
a positive result receive intrapartum prophylaxis [1]. The
universal treatment arm involved administering intrapartum
prophylaxis to all previously colonized women when they
presented in labor [5]. For simplifying assumptions, no delay
in the availability of the GBS culture was assumed. We
assumed that the culture is 100% sensitive in identifying
colonized women and that antibiotic prophylaxis would be
given in a timely fashion with the goal of two doses of
penicillin (i.e., duration ≥ 4 hours). Since penicillin is the
agent of choice for intrapartum prophylaxis, and is preferred
due to a narrower spectrum of antimicrobial activity, an
alternative analysis utilizing ampicillin was not performed
[1]. We estimated that 55% of women would receive ≥4
hours of intrapartum antibiotics [6, 7]. We excluded from
our calculations the costs to treat maternal postpartum
infections since our focus was on infant-related costs [8].
Cost estimates do not include potential costs of prolonging
the hospital stay (>48 hours postdelivery) for extended
observation or treatment of infants with signs of sepsis.
2.2. Intrapartum Prophylaxis in Patients Reporting a Penicillin
Allergy. Three percent to eight percent of individuals in
the population report an allergy to penicillin [9, 10].
The prevalence of patient-reported penicillin allergy among
GBS-positive women is 8% [11]. We assumed that 8% of
women in our cohort would report an allergy to penicillin,
necessitating prophylaxis with a diﬀerent antibiotic. Current
CDC guidelines recommend that in women with a history
of penicillin allergy, assessment should be undertaken to
determine whether a high risk for anaphylaxis is present [1].
Those considered at low risk for anaphylaxis may be given
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cefazolin without further GBS susceptibility testing. Whereas
penicillin-allergic patients at high risk for anaphylaxis should
have GBS screening with GBS isolates being tested for
resistance to clindamycin and erythromycin. If GBS is
susceptible to both clindamycin and erythromycin, then
either of these antibiotics may be utilized. If the antimicrobial
sensitivity is unknown or if GBS is resistant to clindamycin or
erythromycin, then vancomycin should be given [1].
Since publication of the 2002 CDC guidelines, the largest
study looking at intrapartum GBS prophylaxis in patients
reporting a penicillin allergy, noted of the women who
received appropriate antibiotic prophylaxis, 38% were con-
sidered low risk for anaphylaxis and given a cephalosporin
[11]. Of the 62% of women considered at a high risk for
anaphylaxis, 65% of these women had prophylaxis with
vancomycin. The remaining 35% would have been eligible
for clindamycin or erythromycin. We therefore made the
assumption that 38% of women who reported a history of
an allergy to penicillin who either screened positive for GBS
or were to be given prophylaxis based on past colonization
in a previous pregnancy would be considered low risk for
anaphylaxis and treated with a cephalosporin without GBS
isolates being tested for susceptibility. Of the 62% of women
considered at a high risk of anaphylaxis, GBS screening
would be performed (both in the screen and treat group,
and the universal treatment group), and those colonized with
GBS would have susceptibility testing performed. Antibiotic
prophylaxis would be directed as recommended by the CDC
guidelines [1]. Although susceptibility testing is recommend
for all penicillin-allergic women at high risk of anaphylaxis,
only 11% of samples are reported to have this performed
[11]. We estimated a midpoint of this range (11%–100%),
or a probability of 0.56 for susceptibility testing to be done.
Based on the work of Matteson et al. [11], we assumed
that 65% of these women would have prophylaxis with
vancomycin and the remaining 35% would be eligible for
clindamycin or erythromycin.
2.3. Eﬀectiveness of Each Strategy. The primary measures
of eﬀectiveness of each strategy were (1) the number of
early onset neonatal GBS sepsis cases prevented, (2) the
total cost of intervention, and (3) overall cost-eﬀectiveness.
The baseline eﬃcacy of intrapartum antibiotic prophylaxis,
probabilities for each strategy, and outcomes were derived
from a systematic review of the English literature, supple-
mented by bibliographic review. We examined reference lists
from studies identified as potentially relevant. The following
search terms were used: “group B streptococci,” “group B
streptococcus,” “streptococcus agalactiae,” “pregnancy,” “early
onset neonatal group B streptococcal infection,” “maternal
colonization with streptococcus B,” and combinations thereof,
and the databases queried (January 1966 to January 2009)
include MEDLINE, PubMed, Scopus, Knowledge Finder,
Cochrane database, and the Centers for Disease Control
and Prevention guidelines. The probabilities included in the
decision tree are shown in Table 1. Reporting guidelines for
cost-eﬀectiveness analyses were utilized [24]. We performed
sensitivity analyses to account for uncertainty around vari-
ous measures. Studies utilized for probability estimates were
evaluated for their level of evidence as recommended by the
United States Preventive Services Task Force [25].
2.4. Birth Cohort. A societal perspective for this cost analysis
was performed. In 2007, there were 4 315 000 live births
in the United States of which 2 597 630 (60.2%) were a
second child or greater [26, 27]. Of the total live births,
10.9% are estimated to be repeat cesarean deliveries [28],
12.8% preterm deliveries <37 weeks gestation [27], 0.4%
with a previous infant with GBS disease [19], and 2.0%
with GBS bacteriuria during the current pregnancy [19, 22].
Thus a potential group of 1 748 719 women greater than
37 weeks gestation with a previous vaginal delivery without
a previous infant with GBS disease or GBS bacteriuria in
the current pregnancy will present for labor. It has been
estimated that greater than 90% of women are screened for
group B streptococcus in pregnancy [1]. Depending upon the
population screened, colonization rates for GBS have been
reported to range from 10% to 30% [2]. Assuming that
90% of women were screened in the previous pregnancy and
20% screened positive, then of the 1.7 million multiparous
women presenting in labor, 314 769 may have been colonized
with GBS in their past pregnancy. For ease of calculations,
we rounded this cohort to 300 000 women. Five percent to
11% of women, who are intended to receive prophylaxis for
GBS colonization, will not receive it at the time of delivery
[11, 19]. We assumed that noncompliance with intrapartum
antibiotics would be the same whether the woman presented
with known GBS colonization or with intent to treat based
on past pregnancy colonization. We therefore estimated a
midpoint of this range (5%–11%), or 8% of women would
not receive planned intrapartum antibiotic prophylaxis.
2.5. Probability Estimates. Table 1 lists the probability esti-
mates used in our analyses and the range cited in the
literature. We estimated 0.41 as the probability of recurrence
of GBS colonization in a subsequent pregnancy. Cheng et al.
[3] demonstrated a rate of recurrence of 0.38 as measured
by vaginal-rectal culture in women colonized with GBS in
a subsequent pregnancy. Our prior study showed a similar
rate of recurrence (0.44) in subsequent pregnancies if GBS
colonization was determined by vaginal-rectal culture, and
the rate increased to 0.53 if previous colonization was
identified from urine and vaginal-rectal culture [4]. Since in
the current study we limited our analysis to women without
GBS bacteriuria in the subsequent pregnancy, we estimated
a midpoint of this range as determined by vaginal-rectal
culture (38% to 44%) or a probability of 0.41.
It has been estimated that a colonized gravida who did
not receive intrapartum antibiotics would have a probability
of 0.016 delivering a neonate with early onset neonatal GBS
[8]. A colonized gravida treated with intrapartum antibiotics
has a very low risk of delivering an aﬀected infant. Based
on previous published studies, an infant delivered from a
GBS colonized mother who received intrapartum antibiotic
prophylaxis would have a probability of 0.001 of developing
early onset GBS sepsis [8, 12–17]. It has been assumed that
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Table 1: Probability estimates used in the decision analysis.
Variable Baseline
estimate
Range for
sensitivity analysis
References
Level of
evidence∗
Probability of being colonized with GBS in a subsequent pregnancy
0.41 0.38–0.44 [3, 4] II
Probability of early onset neonatal GBS sepsis if mother colonized and treated
0.001 0–0.011 [12–17] I
Probability of early onset neonatal GBS sepsis if mother colonized and not treated
0.016 0.011–0.066 [8, 13–17] I and II
Probability of early onset neonatal GBS sepsis if mother not colonized and given no treatment
0.0002 0–0.0004 [8, 18] II
Probability of early onset neonatal GBS sepsis if mother not colonized and given treatment
0.00001 0–0.0004 See methods
Probability of not receiving planned antibiotic prophylaxis
0.08 0.05–.11 [11, 19] II
Probability of maternal anaphylaxis to penicillin
Penicillin 0.000205 0.00001–0.0004 [9, 20] II and III
Cephalosporin 0.000215 .000015–0.0004 [20, 21] II and III
Clindamycin 0.00007 0.000003–0.00013 See methods
Erythromycin 0.00007 0.000003–0.00013 See methods
Vancomycin 0.0002 0.00001–0.0004 [21] III
Probability of maternal death from antibiotic anaphylaxis
0.0000175 0.000015–0.00002 [9] III
Probability of individual reporting an allergy to penicillin at high risk of anaphylaxis colonized
with GBS and having susceptibility testing done
0.56 0.11–1 [11] II
Culture positive gravidas receiving ≥4 hours intrapartum antibiotics
0.55 0.53–0.65 [6, 7, 22] II and III
Probability of a newborn limited diagnostic workup born to mothers colonized with GBS
who received <4 hours antibiotics before delivery
0.52 0.04–1 [1, 6, 23] II and III
Probability of obtaining a newborn CBC in neonates born to mothers negative for
GBS colonization
0.07 0–0.14 [6, 23] II
GBS: group B streptococci; CBC: complete blood count.
∗US Preventive Services Task Force (10). Level I is the best evidence, and III is the worst evidence.
Infectious Diseases in Obstetrics and Gynecology 5
only infants of colonized women are at risk for early onset
neonatal sepsis, although the birth of colonized infants to
culture-negative mothers has been reported [12, 13, 29]. The
probability of developing early onset neonatal GBS sepsis if
the mother is not colonized and received no intrapartum
antibiotics ranges from zero to 0.0004 [15]; however, we
utilized 0.0002 as suggested by Benitz et al. [18]. It has been
calculated that a 16-fold decrease in early onset neonatal
GBS sepsis is observed in infants born to colonized mothers
treated with intrapartum antibiotics [8]. We assumed that
at a minimum, a similar decrease in the probability of early
onset GBS sepsis would theoretically occur in a mother
not colonized with GBS who was treated with intrapartum
antibiotics yielding a probability of delivering an infant with
early onset neonatal GBS of 0.00001. The probabilities esti-
mated for the risk of maternal anaphylaxis to antibiotics were
as follows: penicillin 0.000205 [9, 20], cephalosporin 0.00021
[20, 21], and vancomycin 0.0002 [21]. Reports of maternal
anaphylaxis to clindamycin or erythromycin are rare. When
drug induced anaphylaxis is compared, the ratio of penicillin
to erythromycin is 3 to 1 [30]. We therefore assumed that
the rate of an anaphylaxis reaction to erythromycin would
be 3 times less than the risk from penicillin or a probability
of 0.00007. Estimates of anaphylaxis to clindamycin in the
general population are lacking [30]. We assumed that the
rate would not be greater than that seen with erythromycin,
or 0.00007. Maternal deaths from an anaphylactic reaction
were assumed to be similar regardless of the drug which
initiated the event. We therefore utilized the reported rate for
penicillin of 0.0000175 [9].
2.6. Cost Estimates. Estimates for direct medical costs
(Table 2) were obtained from the literature and were adjusted
for inflation to U.S. dollars in 2008 [31]. It was assumed that
a vaginal-rectal culture would be performed for screening
[8, 18, 32–34]. Women colonized with GBS who reported
an allergy to penicillin and were at high risk for anaphylaxis
would have susceptibility testing performed [1, 11, 34]. The
costs of maternal antibiotic prophylaxis were based on the
costs of 5 million units of penicillin G, followed by a second
dose of 2.5 million units. For patients reporting an allergy
to penicillin, cost estimates were based on a single dose
of the following regimens: 2 grams of cefazolin, 1 gram of
vancomycin, or 900mg of clindamycin. For erythromycin
we assumed that 95% would deliver within 6 hours and
would receive only one dose of 500mg [35]. Cost sensitivities
were performed for women eligible for clindamycin or
erythromycin as follows: 100% receiving clindamycin, 100%
receiving erythromycin, or half receiving each. Antibiotic
costs were the average wholesale cost [36]. Although the
average wholesale cost is intended to represent the drug
price for transactions between wholesalers and purchasers, it
may not take into account all of the discounts and rebates
negotiated between the parties in such transactions [37].
Hospital charges for incidental supplies (such as intravenous
tubing, diluents, alcohol swabs, and personnel costs) may
have a large variability as well. We therefore utilized a
sensitivity analysis of 50% more or 50% less of the reported
antibiotic costs to account for these unknown variability’s.
Costs from the medical literature and fee schedules from
government sponsored insurances were utilized for estimates
of the neonatal complete blood count with diﬀerential
and blood culture [22, 34, 38–40]. Costs to treat maternal
complications were calculated from probabilities and costs
of anaphylaxis and maternal death reported in the literature
[8, 33, 38, 39]. The total expected, direct, and indirect costs
for each case of early onset neonatal GBS sepsis in term
infants were obtained from the previous reported estimates
[38, 39, 41, 42].
Past cost analyses have included expenses associated with
cases of neonatal sepsis, but they have not incorporated costs
for the pediatric care received by newborns as a result of GBS
prevention strategies [8, 18]. It has been suggested that such
costs should be included in future cost-eﬀectiveness analyses
[22]. Costs for newborns and their mothers treated with
antibiotics exceed those of mothers and infants not given
antibiotics [38, 39, 43]. The majority of the increasing costs
are due to the CDC guidelines proposing that healthy term
infants whose mothers received <4 hours of intrapartum
antibiotic prophylaxis for GBS should be hospitalized for
48 hours [38, 39]. Pediatric costs of asymptomatic term
infants born to mothers receiving intrapartum prophylaxis
under a culture-based approach were sensitive to changes
in the median length of hospitalization and daily physician
assessments [22, 38, 39]. However, since publication of past
cost-eﬀectiveness analyses, median length of hospitalization
for vaginal deliveries has changed. In 1999, federal legislation
required insurers to cover up to 48 hours of hospitalization
after a vaginal delivery [44]. Studies comparing the length of
stay for infants delivering vaginally whose mother received
intrapartum antibiotics for GBS prophylaxis compared with
those who did not, demonstrated no significant diﬀerence
[6, 23]. Since 2000, length of stay for women delivering
vaginally and their “well infants” has averaged 2.1 days
[45]. We therefore made the assumption that the length of
hospitalization in women undergoing a vaginal delivery of a
healthy neonate would not be significantly diﬀerent whether
intrapartum antibiotic prophylaxis was given or not.
2.7. CDC Guidelines’ Eﬀect on Neonatal Care. In 2002, the
CDC proposed revised guidelines for the management of a
newborn whose mother received intrapartum antibiotics for
prevention of early onset GBS disease [1]. These guidelines
recommend that pediatricians observe asymptomatic full-
term infants for 24 to 48 hours (dependant upon discharge
criteria) if their mother received >4 hours of intrapartum
antimicrobial prophylaxis. If mothers at risk receive <4
hours of intrapartum antibiotics, pediatricians should order
a complete blood count, a blood culture, and observe infants
for 48 hours (i.e., a limited evaluation). A full diagnostic
evaluation and empiric therapy is initiated only if sepsis is
suspected. Although the algorithm recommends that only
neonates with symptoms of sepsis undergo a diagnostic
workup, clinicians are more likely to pursue diagnostic test-
ing if the mother received prophylactic intrapartum antibi-
otics, regardless of the infant’s signs and symptoms [23].
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Table 2: Costs (in 2008 USD) included in decision tree.
Variable Baseline estimate Range for sensitivity analysis Source or references
Cost of GBS rectal-vaginal culture
$50 $30–$75 [8, 18, 32, 34, 41]
Cost of GBS rectal-vaginal culture with susceptibility testing [34]
$59 $35–$89 [36]
Cost of maternal antibiotic therapy
One dose of 5 million units of penicillin G
$18 $9–$27
Second dose of 2.5 million units of penicillin G
$11 $6–$17
One dose of 2 grams of cefazolin
$14 $7–$21
One dose of 900 milligrams of clindamycin
$18 $9–$27
One dose of 500 milligrams of erythromycin
$16 $8–$24
One dose of 1 gram of vancomycin
$12 $6–$18
Cost of neonatal CBC [22, 34, 38, 39]
$15 $8–$41
Cost of neonatal blood culture [22, 34, 40]
$20 $10–$26
Cost of maternal anaphylaxis case
$11 160 $1186–$30 286 [8, 33, 38, 39]
Cost of maternal death due to anaphylaxis
$1 211 432 $1 090 288–$1 332 575 [8]
Direct cost of early onset GBS sepsis case term infant
$19 774 $17 723–$21 824 [38, 39, 41]
Total (direct and indirect) cost of early onset GBS sepsis case term infant
$81 599 $67 764–$95 433 [38, 39, 42]
GBS: group B streptococci; CBC: complete blood count.
Practitioners managing newborns noted that among infants
with no signs of sepsis, 20% of neonates whose mothers
received intrapartum antibiotics had a CBC, compared with
4% of neonates whose mothers did not receive intrapartum
antibiotics [23]. Further, only 4% of infants born to mothers
who received intrapartum antibiotics, regardless of whether
it was less or greater than 4 hours before delivery, had blood
cultures [23]. Since studies suggest that a limited diagnostic
workup varies regardless of whether a mother received <4
hours of intrapartum antibiotics, we estimated a midpoint
of this range (4% to 100%) or a probability of 0.52 that both
a CBC and blood culture would be obtained [1, 6, 23]. If >4
hours of intrapartum antibiotics were received, we assumed
that no additional diagnostic evaluation would be performed
except for the usual 48 hours of newborn observation.
2.8. Cost-Eﬀectiveness Analysis. In the baseline analysis,
pathway probabilities were used to calculate costs, number
of cases of early onset GBS sepsis prevented, and number of
neonatal deaths and morbidity prevented by each strategy. A
cost-utility analysis was also performed and reported as cost-
eﬀectiveness ratios. The incremental cost-eﬀectiveness ratio
represents supplementary costs of changing from a paradigm
of using screening with treatment of positive results versus
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treatment of all previously GBS positive women. The number
of life-years was set at 80.4 years or 31.1 years with 3%
discounting [46]. Term GBS cases with long-term sequelae
attributable to GBS infection are estimated to be 0.016 [38,
39]. In adjusting for long-term sequelae of early onset GBS
disease in a term infant, a health-related quality of life score
of 0.972 was utilized from prior studies which resulted in an
estimate of 78.1 years, and with 3% discounting, this number
becomes 30.2 years [42].
To calculate the cost per case prevented, we divided
the intervention costs by the number of cases of neonatal
GBS disease prevented. The benefit-cost ratio was calculated
by dividing the monetary savings from preventing disease
by the intervention costs. The total costs expected for
each strategy were calculated by subtracting the cost for
treatment of neonatal GBS disease from the intervention
costs of neonatal GBS disease. To determine the expected net
benefits, we compared total costs with the costs of treating
cases of neonatal GBS disease in the cohort of women if no
prevention strategy is used. Data were managed using Excel
spreadsheet software (Microsoft Corp, Redmond, WA).
3. Results
In the absence of screening or risk-based strategies, 2003 of
the 300 000 newborns were estimated to have early onset
GBS disease, of which 60 (3%) would have died [8, 42, 47],
and of the remaining survivors, 31 (1.6%) would have long
term sequelae [38, 39, 42]. Total cost for treatment of the
2003 term GBS sepsis cases would be $163 442 797 (range
$135 731 292 to $191 152 299, are Table 2). Using the baseline
assumptions, the model favors universal treatment of term
women with intrapartum antibiotic prophylaxis for GBS if
they were colonized in a previous pregnancy as the most
cost-eﬀective strategy as compared to screening and treating
only positive culture results. The costs per quality-adjusted
life-year gained from each strategy are shown in Table 3.
The conclusions were not aﬀected by varying the antibiotic
regimen utilized in women at high risk of anaphylaxis
(using either clindamycin or erythromycin) or if all women
eligible for susceptibility testing for GBS had this performed
(data not shown). Universal treatment with intrapartum
antibiotics resulted in an incremental cost savings of $209 988
(range $113 920 to $329 258) per quality-adjusted life-year
gained when compared to treatment directed by screening.
The cost for each case of early onset GBS sepsis prevented
using intrapartum antibiotic prophylaxis directly was $8805
(range $5 639 to $12 998), compared with $12 710 (range
$7773 to $19 105) for women screened then treated. The
annual cost savings for the cohort of women in 2007 with
direct intrapartum treatment in the U.S. would be $6.35
million (range $3.45 to $9.97 million). When sensitivity
analyses were performed for the incidence of recurrent GBS
colonization in a subsequent pregnancy, universal treatment
remained cost-eﬀective to an incidence as low as 10%. A
sensitivity analysis was performed with identical baseline
assumptions but presumed that all infants receiving <4 hours
of intrapartum antibiotics would have a complete blood
count and blood culture, and all penicillin-allergic patients
at high risk for anaphylaxis would have GBS screening
with GBS isolates being tested for resistance to clindamycin
and erythromycin (i.e., strict adherence to the CDC algo-
rithm). Universal treatment with intrapartum antibiotics
resulted in an incremental cost savings per quality-adjusted
life-year gained of $154 063 (range $84 804 to $226 553)
when compared to treatment directed by screening. The
cost for each additional case of early onset GBS sepsis
prevented using intrapartum antibiotic prophylaxis directly
was $10 226 (range $6371 to $15 708), compared with $13354
(range $8108 to $20 322) for women screened then treated
with an annual cost savings for this cohort of $4.96 million
(range $2.73 to $7.29 million).
We considered the results of altering the cost of each
variable in Table 2 over the range of costs estimated from
the medical literature. Using the baseline assumptions, the
model always favored universal treatment of term women
with intrapartum antibiotic prophylaxis for GBS if they were
colonized in a previous pregnancy as the most cost-eﬀective
strategy as compared to screening and treating only positive
culture results. Only in the scenario where all infants who
received <4 hours of intrapartum antibiotics had a limited
diagnostic evaluation (i.e., strict adherence to the CDC
algorithm) did the cost of a GBS culture impact the cost-
eﬀectiveness of universal (direct) treatment when compared
to screening-directed treatment. In this ideal situation, if the
cost of a GBS culture became $33 or less, screening-directed
treatment would be more cost-eﬀective.
4. Discussion
This analysis illustrates that universal treatment in sub-
sequent pregnancies of women with a history of GBS
colonization is a more cost-eﬀective strategy for reducing
neonatal early onset GBS disease. Administration of intra-
partum antibiotics to women with history of colonization
in past pregnancies could prevent substantial disease and
save millions of dollars annually compared to the current
screening-directed treatment approach.
Cost-eﬀectiveness analysis has been advocated as a basic
tool in the evaluation of health care practices [48]. When
uncertainty exists about the appropriate clinical strategy for
patients with a given health state, or when a randomized
prospective trial is not feasible, policy makers may utilize
cost-eﬀectiveness analysis to guide decisions for intervention.
Current treatment guidelines from the CDC and ACOG
recommend that women colonized with GBS in previ-
ous pregnancies undergo universal antenatal culture-based
screening at 35 to 37 weeks of gestation to direct treatment
for the prevention of early onset GBS disease [1, 2]. How-
ever, despite these recommendations, some obstetricians
administer antibiotic prophylaxis based on prior history of
GBS colonization [4, 5]. When surveyed, obstetricians in
the U.S. have shown a preference for strategies for GBS
prophylaxis not described in consensus guidelines with the
most common strategy providing intrapartum antibiotics
to all GBS colonized women and women with negative
screening cultures who develop risk factors [49]. The optimal
decision in this scenario should be based on a randomized
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Table 3: Estimated eﬀects and costs (in 2008 USD) of the diﬀerent treatment strategies compared with a situation without treatment for a
birth cohort of 300 000 infants born to mothers colonized with GBS in a previous pregnancy (3% discounting).
Screen and
treat strategy
Universal
treatment strategy
Eﬀects
EOGBS cases
prevented
1700 1732
Deaths due to EOGBS
prevented
51 52
QALY gained 1607 1637
Range∗ Range∗
Cost (in dollars)
Costs of screening 15 000 000 9 000 000–22 500 000 NA
Cost of IAP with
penicillin
2 503 778 1 280 519–3 784 297 6 106 776 3 123 216–9 229 992
Cost of screening and
treating women with
a history of a
penicillin allergy
154 551 79 011–233 562 223 856 113 664–337 519
Treatment for
maternal anaphylaxis
and death
2 658 264 2 188 173–3 339 396 6 293 596 5 178 717–7 910 099
Cost of limited
evaluation of well
infants whose
mothers received <4
hours of IAP
1 104 569 568 064–2 114 460 2 617 008 1 345 890–5 009 702
Cost of CBC of well
infants whose mother
was negative for GBS
185 850 99 120–507 990 9 367 4 996–25 603
Total costs for
treatment of term
GBS sepsis cases
−24 719 871 20 528 650–28 910 788 −22 111 508 18 362 532–25 860 213
Total costs of
intervention
21 607 013 13 214 887–32 479 706 15 250 603 9 766 483–22 512 915
Numbers needed to
treat per GBS case
prevented
67 155
Cost-eﬀectiveness (in
dollars)
Cost savings per
QALY gained
72 878 78 100–66 112 77 006 80 355–72 570
Cost for each GBS
case prevented
12 710 7 773–19 105 8 805 5 639–12 998
Benefit-cost ratio 6.4 10 5–4.3 9.3 14.5–6.3
Total annual costs net
benefits
141 835 784 150 227 910–130 963 091 148 192 194 153 676 314–140 929 882
EOGBS: early onset group B streptococci; QALY: quality-adjusted life-year gained; IAP: intrapartum antibiotic prophylaxis; GBS: group B streptococci; CBC:
complete blood count. NA: not applicable.
∗Range: it is the cost utilizing the baseline probability estimates from Table 1 and the lowest to the highest estimates shown in Table 2.
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controlled trial. However, to detect a diﬀerence in the rate of
early onset GBS sepsis between the two strategies compared
would require over 5000 women in each arm of the trial.
Specific concerns about universal antibiotic prophylaxis
hinge on the possibility of adverse antibiotic reactions and
the development of antimicrobial resistance [33]. Neverthe-
less, the strategy of universal treatment is based on past
GBS colonization in which most women would have received
antibiotics in the previous pregnancy. The incidence of
anaphylaxis from an initial penicillin exposure compared to
a subsequent exposure have not been shown to be diﬀerent
(0.1 per 10 000 dispensing) [20]. However, case reports of
women given intrapartum prophylaxis for GBS who received
previous penicillin-related antibiotics without allergic reac-
tions have had subsequent episodes of anaphylaxis [50]. In
addition, the costs of treating other antibiotic associated
adverse medical events such as pseudomembranous colitis
were not included in the current analysis. Past studies have
not shown an increase in these events when antibiotic pro-
phylaxis was introduced for neonatal GBS disease prevention
[6]. Theoretical risk of selecting antibiotic-resistant GBS or
alteration of neonatal flora allowing for early onset neonatal
sepsis attributable to other pathogens such as Escherichia coli
has been raised [8]. With more than 40% of mothers receiv-
ing intrapartum antibiotics for GBS prevention, cesarean
prophylaxis, or clinical chorioamnionitis [43], emerging
resistance of GBS to erythromycin and clindamycin has been
reported [51]. Despite the appearance of increasing number
of resistant GBS strains, GBS remains universally sensitive
to penicillin [51]. Exposure to ß-lactam antibiotics (either
ampicillin or penicillin) for intrapartum GBS prophylaxis
has been associated with increases in postpartum ampicillin-
resistant organisms [52]. However, despite the common
use of intrapartum antibiotic prophylaxis, increased rates
of early onset neonatal infection with ampicillin-resistant
gram-negative organisms has not been seen in term infants,
andmoreover, intrapartum antibiotic prophylaxis has shown
a protective eﬀect [53]. This current data suggest that the
potential tradeoﬀ of widening the scope of intrapartum
antibiotic administration would not impact the rate of early
onset neonatal sepsis in term infants attributable to other
pathogens.
Our study has several limitations. The current analysis
focuses on the prevention of early onset GBS neonatal
sepsis. No costs or outcomes were included to treat maternal
pregnancy-associated disease or for infants who developed
late-onset GBS disease. However, the incidence of late-onset
GBS neonatal sepsis has not been shown to be impacted by
intrapartum antibiotic prophylaxis [47].The present analysis
is limited by estimates of cost from the medical literature
and fee schedules from government sponsored insurances.
The utilization of the average wholesale price for estimates
of drug costs has been the subject of extensive criticism for
its failure to reflect actual prices paid in the market [37].
Values reported in the medical literature for two doses of
penicillin which included costs for supplies and personnel
(adjusted for inflation to 2008), range between $38 to $48,
similar to the range of our estimate [32, 38, 39]. However,
sensitivity analyses were performed over a wide array of
cost values available. We assumed that obstetricians would
have access to the results of a patient’s GBS status from her
prior pregnancy. With the integration of electronic medical
records in obstetrics and patient education of the impact of
past pregnancy GBS colonization, knowledge of this in future
pregnancies could be available. In addition, we assumed
that in women undergoing an uncomplicated term vaginal
delivery that the length of hospitalization would not diﬀer
based on receiving intrapartum antibiotics. Studies compar-
ing average length of stay for newborns whose mothers were
treated with intrapartum antibiotics have had conflicting
results [6, 23, 43]. However these studies predominately
evaluated hospital length of stay prior to the implementation
in 1999 of federal legislation requiring insurers to cover up to
48 hours of hospitalization after a vaginal delivery [44]. Since
2000, the length of stay for womenwith vaginal deliveries and
their “well infants” has averaged >48 hours [40]. This average
length of stay did not change after implementation of CDC
guidelines for GBS prophylaxis in 2002. Finally, the results of
cost-eﬀectiveness analysis rest on the baseline assumptions
put into the model which is limited by the quality and
quantity of the available information. Since no measures
of inherent variability (i.e., probabilities with confidence
intervals) in the form of statistical analyses are utilized, one
must interpret the results of cost-eﬀectiveness analysis with
this in mind.
5. Conclusions
Our analysis suggests that in this well defined popula-
tion, universal intrapartum antibiotic prophylaxis in future
pregnancies of women with GBS colonization in a prior
pregnancy could prevent disease and represent a cost-savings
compared to current screening strategies for prevention of
early onset GBS infection.
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